Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Revenue (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Revenue for 5 consecutive years, with $10.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Revenue rose 2177.9% to $10.0 million in Q3 2025 year-over-year; TTM through Dec 2025 was $10.0 million, a 5.55% decrease, with the full-year FY2025 number at $10.0 million, down 5.55% from a year prior.
  • Revenue was $10.0 million for Q3 2025 at Janux Therapeutics, up from $439000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $10.0 million in Q3 2025 to a low of $380000.0 in Q1 2021.
  • A 5-year average of $2.6 million and a median of $1.7 million in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: plummeted 82.56% in 2024, then skyrocketed 2177.9% in 2025.
  • Janux Therapeutics' Revenue stood at $1.6 million in 2021, then surged by 76.05% to $2.8 million in 2022, then fell by 13.5% to $2.5 million in 2023, then crashed by 82.16% to $439000.0 in 2024, then surged by 2177.9% to $10.0 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Revenue are $10.0 million (Q3 2025), $439000.0 (Q3 2024), and $8.9 million (Q2 2024).